UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.